Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Clinical treatment programs – US	$ 202	$ 141
Total Revenues	202	141
Costs and Expenses:
Production costs	42
Research and development	10,939	6,990
General and administrative	21,137	13,074
Total Costs and Expenses	32,118	20,064
Operating loss	(31,916)	(19,923)
Gain (loss) on investments	200	(1,679)
Interest and other income	1,069	629
Gain on sale of fixed assets	18	3
Redeemable warrants valuation adjustment		35
Gain from sale of income tax operating losses	1,667	1,490
Net Loss	$ (28,962)	$ (19,445)
Basic loss per share	$ (0.60)	$ (0.40)
Diluted loss per share	$ (0.60)	$ (0.40)
Weighted average shares outstanding basic	48,585,404	48,047,288
Weighted average shares outstanding diluted	48,585,404	48,047,288